N
Norman T. Ilowite
Researcher at Albert Einstein College of Medicine
Publications - 141
Citations - 10448
Norman T. Ilowite is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Arthritis & Juvenile rheumatoid arthritis. The author has an hindex of 51, co-authored 141 publications receiving 9503 citations. Previous affiliations of Norman T. Ilowite include Yeshiva University & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Daniel J. Lovell,Edward H. Giannini,Andreas Reiff,Gail Cawkwell,Earl D. Silverman,James J. Nocton,Leonard D. Stein,Abraham Gedalia,Norman T. Ilowite,Carol A. Wallace,James B Whitmore,Barbara K. Finck +11 more
TL;DR: Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis and is well tolerated by pediatric patients.
Journal ArticleDOI
2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features
Timothy Beukelman,Nivedita M. Patkar,Kenneth G. Saag,Sue Tolleson-Rinehart,Randy Q. Cron,Esi Morgan DeWitt,Norman T. Ilowite,Yukiko Kimura,Ronald M. Laxer,Daniel J. Lovell,Alberto Martini,C. Egla Rabinovich,Nicolino Ruperto +12 more
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Journal ArticleDOI
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli,Francesca Minoia,Sergio Davì,AnnaCarin Horne,Francesca Bovis,Angela Pistorio,Maurizio Aricò,Tadej Avcin,Edward M. Behrens,Fabrizio De Benedetti,Lisa Filipovic,Alexei A. Grom,Jan-Inge Henter,Norman T. Ilowite,Michael B. Jordan,Raju Khubchandani,Toshiyuki Kitoh,Kai Lehmberg,Daniel J. Lovell,Paivi Miettunen,Kim E. Nichols,Seza Ozen,Jana Pachlopnik Schmid,Athimalaipet V Ramanan,Ricardo Russo,Rayfel Schneider,Gary Sterba,Yosef Uziel,Carol A. Wallace,Carine Wouters,Nico M Wulffraat,Erkan Demirkaya,Hermine I. Brunner,Alberto Martini,Nicolino Ruperto,Randy Q. Cron +35 more
TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.
Journal ArticleDOI
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series
Peter A. Nigrovic,Melissa L. Mannion,Femke H. M. Prince,Andrew Zeft,C. Egla Rabinovich,Marion A J van Rossum,Elisabetta Cortis,Manuela Pardeo,Paivi Miettunen,Ginger Janow,James Birmingham,Aaron Eggebeen,Erin Janssen,Andrew I. Shulman,Mary Beth F. Son,Sandy D. Hong,Karla N. Jones,Norman T. Ilowite,Randy Q. Cron,Gloria C. Higgins +19 more
TL;DR: Anakinra as first-line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined.
Journal ArticleDOI
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
Daniel J. Lovell,Andreas Reiff,Andreas Reiff,Norman T. Ilowite,Carol A. Wallace,Yun Chon,Shao Lee Lin,Scott Baumgartner,Edward H. Giannini +8 more
TL;DR: These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients.